Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Wednesday, September 9, 2015

Sovaldi-Based Hep C Regimens Less Successful in Real World

The real-world cure rates offered by Sovaldi (sofosbuvir)–based hepatitis C virus (HCV) regimens have not been as good as those seen in clinical trials, at least among a group of veterans with genotypes 1 or 2, Healio reports. Publishing their findings in Alimentary Pharmacology & Therapeutics, researchers analyzed data from the Veterans Affairs Clinical Case Registry for HCV on 4,026 vets treated for hep C with 12-week Sovaldi–based regimens.

A total of 3,203 of the vets had genotype 1 and 823 had genotype 2.

Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) has superseded Sovaldi–based regimens (Sovaldi is also a Gilead drug) as the treatment of choice for those with genotype 1. So this study’s findings may not be applicable to the current realities of hep C treatment among that group, especially since this study looked in part at the results of regimens including interferon, which causes flu-like side effects. Interferon has largely been edged out of the hep C arsenal.

However, 12 weeks of Sovaldi plus ribavirin is still the top-recommended regimen for treatment-naive people with genotype 2, which makes  this study more relevant to that population’s current concerns.

Read more...

No comments:

Post a Comment